Issue Date: September 28, 2009
Qiagen Acquires Diagnostics Maker
Qiagen, a Dutch assay technology company, has acquired DxS, a diagnostics firm, for $95 million in cash, plus up to $35 million more if certain milestones are met. Based in Manchester, England, DxS develops molecular diagnostic assays that allow oncologists to predict patient response to cancer treatments. Qiagen says DxS’s products work well with its own automation instruments.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society